2CAROLYN L WANG, RICHARD H, COHAN,et al. Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69657 ntravenous injections [J]. Radiology, 2007,243:80-87.
3HANS H, SCHILD,CHRISTIANE K, et al. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: A prospective randomized controlled trial[J]. Radiology, 2006,240 : 56-64.
1Pintaske J, Martirosian P, Graf H, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobehate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla[J]. Invest Radiol, 2006, 41 (3): 213-221.
2Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents [ J ]. Contrast Media Mol Imaging, 2006, 1 (3): 128- 137.
3Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol [J]. Eur Radiol, 2002, 12(6): 1550-1556.
4Balzer JO, Loewe C, Davis K, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material [J]. Eur Radiol, 2003, 13 (9): 2067-2074.
5Bangartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? [J]. MAGMA, 2007, 20(2): 57-62.
6Le Due G, Corde S, Charvet AM, et al. In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobutrol[J]. Invest Radiol, 2004, 39(7): 385-393.
7Hartmann M, Forsting M, Jansen O, et al. Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas? [J]. Rofo, 1996, 164(2): 119-125.
8Lemke A J, Sander B, Balzer T, et al. Safety and use of gadobutrol in patients with brain tumors (phase HI trial) [J]. Rofo, 1997, 167(6): 591-598.
9Knauth M, Forsting M, Hartmann M, et al. MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer[J]. AJNR, 1996, 17(10): 1853-1859.
10Uysal E, Erturk SM, Yildirim H, et al. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions [J]. AIR, 2007, 188(3): 697-702.
